Ubs Group Ag Cyteir Therapeutics, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$1.74 - $2.6 $769 - $1,149	442 Added 9.16%	5,267 $13,000
Q1 2023 May 12, 2023	BUY	$1.47 - $1.84 $7,092 - $8,878	4,825 New	4,825 $8,000
Q3 2022 Nov 10, 2022	BUY	$1.99 - $4.05 $10,891 - $22,165	5,473 Added 18.66%	34,809 $67,000
Q2 2022 Aug 10, 2022	SELL	$1.62 - $4.4 $3,798 - $10,318	-2,345 Reduced 7.4%	29,336 $88,000
Q1 2022 May 16, 2022	SELL	$3.39 - $10.51 $9,932 - $30,794	-2,930 Reduced 8.47%	31,681 $120,000
Q4 2021 Feb 14, 2022	BUY	$9.83 - $19.21 $336,107 - $656,828	34,192 Added 8160.38%	34,611 $394,000
Q3 2021 Nov 15, 2021	SELL	$14.57 - $21.86 $451 - $677	-31 Reduced 6.89%	419 $7,000
Q2 2021 Aug 13, 2021	BUY	$16.8 - $21.4 $7,560 - $9,630	450 New	450 $10,000

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.